Observational studyAntimicrobial agents and chemotherapy2015
Candida infective endocarditis: an observational cohort study with a focus on therapy.
Observational study in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review.Brazilian journal of cardiovascular surgery · 2020Pooled it
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Diagnostic, cardiac imaging, and management considerations in fungal infective endocarditis: a contemporary narrative review.Cardiovascular diagnosis and therapy · 2026Review
- Impact ofMolecular imaging and radionuclide therapy · 2026Article
- DisseminatedMedical mycology case reports · 2026Article
- Infective Endocarditis: A Contemporary Review of Epidemiology, Diagnosis, and Management.Antibiotics (Basel, Switzerland) · 2026Review
- Heart Transplantation as Salvage Therapy of Candida tropicalis Prosthetic Aortic Valve Endocarditis.JACC. Case reports · 2026Article
- Current Management of Infective Endocarditis: A Narrative Review Focused on Unmet Clinical Needs and the Multidisciplinary Approach.Journal of cardiovascular development and disease · 2026Review
- Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections.Scientific reports · 2025Article
- Nationwide epidemiology of candidiasis in Panama, 2010-2020.Scientific reports · 2025Article
- Fatal Complications inJournal of fungi (Basel, Switzerland) · 2025Article
- Candida Right-Sided Infective Endocarditis.Cureus · 2025Article
- Article
- Contemporary Cleveland Clinic experience of fungal infective endocarditis: a focus on imaging and outcomes.European heart journal. Imaging methods and practice · 2025Article
- Candida parapsilosis Endocarditis of the Native Tricuspid Valve in a Patient Without Common Risk Factors.JACC. Case reports · 2025Article
- Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.Research square · 2025Article
- A Review of Current Insights in Fungal Endocarditis.Journal of clinical medicine · 2025Review
- First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study.Open heart · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida infective endocarditis is a rare disease with a high mortality rate. Our understanding of this infection is derived from case series, case reports, and small prospective cohorts. The purpose of this study was to evaluate the clinical features and use of different antifungal treatment regimens for Candida infective endocarditis. This prospective cohort study was based on 70 cases of Candida infective endocarditis from the International Collaboration on Endocarditis (ICE)-Prospective Cohort Study and ICE-Plus databases collected between 2000 and 2010. The majority of infections were acquired nosocomially (67%). Congestive heart failure (24%), prosthetic heart valve (46%), and previous infective endocarditis (26%) were common comorbidities. Overall mortality was high, with 36% mortality in the hospital and 59% at 1 year. On univariate analysis, older age, heart failure at baseline, persistent candidemia, nosocomial acquisition, heart failure as a complication, and intracardiac abscess were associated with higher mortality. Mortality was not affected by use of surgical therapy or choice of antifungal agent. A subgroup analysis was performed on 33 patients for whom specific antifungal therapy information was available. In this subgroup, 11 patients received amphotericin B-based therapy and 14 received echinocandin-based therapy. Despite a higher percentage of older patients and nosocomial infection in the echinocandin group, mortality rates were similar between the two groups. In conclusion, Candida infective endocarditis is associated with a high mortality rate that was not impacted by choice of antifungal therapy or by adjunctive surgical intervention. Additionally, echinocandin therapy was as effective as amphotericin B-based therapy in the small subgroup analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.